丙型肝炎病毒包膜蛋白E1的分泌表达及性质

为了实现HCV包膜蛋白E1在哺乳动物细胞中的分泌表达,选用分泌表达载体pSecTagB,构建了3种E1羧端不同程度缩短的融合表达质粒,并在E1的上游融合乙型肝炎病毒前表面抗原S1中含肝细胞结合位点的免疫表位preS1(21-47）序列作为标识。在HeLa细胞中进行了暂时表达,并对产物的性质进行了鉴定。去除羧端疏水区有利于E1融合蛋白的分泌,其中以S1E1t325分泌最佳。表达的融合蛋白都能被preS1单抗及HCVE1多抗识别,是具有双重抗原性的糖蛋白,其糖链类型为高甘露糖型。建立了稳定表达S1E1t310、S1E1t325、S1E1t340的CHO细胞株,选择其中CHO／pSecS1E1t325对表达的分泌蛋白作了进一步研究。利用亲和纯化方法可由细胞培养液中富集和纯化分泌表达的HCV E1,为进一步开展E1性质的研究创造了条件。     

融合有HBV前S1（21—47）片段的HCV E2糖蛋白 在CHO细胞中的表达和鉴定

在构建丙型肝炎病毒（HCV）被膜蛋白E2的CHO细胞稳定表达株时,为了方便进行表达产物的检测和纯化,将编码E2N端277个氨基酸（384－661）的基因片段和编码乙型肝炎病毒前S1（21－47）区的基因融合,一起插入分泌表达载体pSecTagB,所得重组质粒转染的CHO细胞经Zeocin选择,得到稳定细胞株CHO（／sS1E2,以E2和preS1特异的抗体进行免疫印迹分析,从筛选到的稳定细胞株检测到了分泌的以及细胞内的表达产物,用糖链类型特异的糖苷酶对表达产物进行了酶解分析,发现绝大多数胞内的E2糖蛋白产物是高甘露糖型的,而分泌的E2糖蛋白产物则绝大多数是复杂糖化的,表明表达的E2在分泌过程中经历了高尔基体的进一步修饰,初步的分析显示,融合抗原能特异地和前S1抗体偶联的Sepharose结合,并能被顺利地洗脱,表明该免疫亲和介质能用于融合抗原的大规模制备,为进一步研究HCVE2糖蛋白的免疫学性质以及重组的HBV／HCV双价疫苗创造了条件。     

我国丙型肝炎病毒囊膜蛋白E2高变区1的序列特征

对２３例国内献血员、血透析及肝炎病人血清用反转录巢式ＰＣＲ技术扩增了ＨＣＶＲＮＡ囊膜蛋白２基因的ｃＤＮＡ片段,并进行了序列测定。结果表明２３例病人ＨＣＶＥ２／ＮＳ１Ｎ末端的核苷酸及氨基酸序列呈现多样性,高变区１（ＨＶＲ１）位于核苷酸第１４５９～１５５９位,氨基酸第３８４～４１０位;我国ＨＣＶ株ＨＶＲ１２７个氨基酸中有１５个位置氨基酸相对稳定,氨基酸组成与分布均与Ｓｅｋｉｙａ报道的１６６个ＨＣＶ株的不同。结果提示,研究我国ＨＣＶ株ＨＶＲ１的序列特征有助于ＨＣＶ的流行病学研究,对研制适用于我国的抗体诊断试剂盒及进行疫苗研究均有重要的意义。     

四份中国HCV阳性血清中包膜蛋白E1/E2准种基因的序列分析及新型插入突变的发现

为分析四份中国丙型肝炎病毒（HCV）阳性血清中包膜蛋白E1/E2基因的准种特征。本研究对从4份中国HCV阳性血清（1b亚型：274、366、383;2a亚型：283）中提取的HCV核酸,采用逆转录-聚合酶反应扩增编码全长E1/E2蛋白（191～764aa）的基因片段,随机挑取多个克隆测序。根据E1/E2基因核苷酸的序列与其他相关序列（来自于GenBank）构建亲缘性关系进化树,进行核苷酸与氨基酸同源性分析并对重要的基因位点进行分析。共获得阳性克隆序列43个（274株10个,283株12个,366株13个,383株8个）,发现高变区HVR1、HVR2的基因异质性高,而其他抗体中和表位及跨膜区I、II及N末端糖基化位点相对保守。并首次发现在HCV 2a亚型（283血清）中多个准种序列存在1279nt（E1区,313aa）处单碱基插入优势基因突变,导致HCV包膜蛋白编码突变与中断（E2区,398aa）。本研究对中国HCV代表株包膜蛋白E1/E2编码基因的准种多样性及一种新型插入突变进行了描述,可为进一步研究HCV免疫逃避与慢性化机制提供重要信息。关键词：丙型肝炎病毒;包膜蛋白;序列分析;准种;插入突变     

肝癌病人血清中丙型肝炎病毒E2／NS1基因区cDNA的克隆及序列分析

从一个抗丙型肝炎病毒（ＨＣＶ）阳性的肝细胞癌（ＨＣＣ）病人血清中提取ＲＮＡ,随机引物逆转录为ｃＤＮＡ后,用ＨＣＶ特异引物进行聚合酶链反应。将扩增产的７８０ｂｐ插入ｐＵＣ１８和ｐＵＣ１９质粒载体,双脱氧链末端终止法测定其序列。与慢性丙型肝炎病人或携带者血清中的ＨＣＶ序列比较,核苷酸同源性介乎６９．２３％－８９．１０％,氨基酸同源性介乎７４．５９％－９０．５７％,分析表明,此序列属于１组Ⅱ型。本文结果     

丙型肝炎病毒E1蛋白活化MAPK／ERK信号通路促进肝癌细胞增殖

目的研究丙型肝炎病毒（hepatitisCvirus,HCV）编码蛋白E1的生物学功能。方法分别构建编码HCV重要蛋白E1、E2、NS3、NS5a、NS5b的腺病毒载体Ad—E1、Ad—E2、Ad—NS3、Ad—NS5a、Ad—NS5b;将重组并包装的腺病毒分别感染SMMC-7721细胞,测定感染滴度,通过RT—PCR方法在转录水平鉴定HCVE1、E2、NS3、NS5a、NSSb的表达,用Western印迹在蛋白水平鉴定E1蛋白的表达。腺病毒感染SMMC-7721细胞后,通过细胞增殖实验筛选生物学功能最明显的蛋白。将筛选到的Ad—E1感染SMMC-7721细胞,用MTS、结晶紫、细胞周期实验观察体外过表达E1蛋白对感染细胞增殖的影响;Western印迹检测p-ERK、ERK的表达;RT—PCR检测c—Myc、cyclinD1、c—Jun、c．Fos基因的表达。结果成功扩增了能够编码HCV重要蛋白E1、E2、NS3、NS5a、NS5b的高滴度腺病毒Ad—E1、Ad—E2、Ad—NS3、Ad—NS5a、Ad—NS5b,并且通过RT—PCR方法在转录水平鉴定了目的基因的表达,Western印迹方法在蛋白水平鉴定了E1蚩白的表达。通过细胞计数、MTS、结晶紫实验证实Ad—E1感染组细胞较对照组增殖速度加快,细胞周期显示Ad-E1感染组细胞34．38％处于S期,明显高于Ad—GFP（27．32％）（P〈0．05）对照组;Ad-E1感染绢p-ERK蛋白表达量增高,同时与细胞增殖相关的MAPK／ERK下游基因转录水平上凋。结论体外过表达HCVE1蛋白可以明显促进SMMC-7721细胞的增殖,其促增殖作用可能与MAPK／ERK信号通路的活化相关。     

庚型肝炎病毒包膜蛋白E2抗体的研究进展

用酶联免疫吸附试验（ＥＬＩＳＡ）检测血清庚型肝炎病毒（ＧＢＶ－Ｃ／ＨＧＶ，以下简称ＨＧＶ）胞膜蛋白Ｅ２抗体是新建立的一种实验室检测方法。这种抗体像是一种中和抗体，是ＨＧＶ既往感染的标志，在清除病毒血症和阻止再感染方面起重要的作用，但不是判断有无传染性的标准，也不能用它准确地评价人群中的病毒感染状况。     

丙型肝炎病毒C+E1区基因在原核细胞中的克隆与表达

将丙型肝炎病毒Ｃ＋Ｅ１区基因插入到原核高效表达载体ｐＢＶ２２１质粒中,构建了质粒ｐＢＶ２２１ＨＣＶ／Ｃ＋Ｅ１作为表达载体,然后,将含有该质粒的宿主大肠杆菌进行升温诱导表达ＨＣＶ／Ｃ＋Ｅ１区基因,并对表达产物进行了生物活性的检测。结果表明,插入到表达载体ｐＢＶ２２１中的ＨＣＶ／Ｃ＋Ｅ１基因片段能够得到有效的表达,表达产物主要为非融合蛋白形式存在于细胞中,同时这种Ｃ区和Ｅ１区连接共表达的产物保持了良好的抗原活性     

丙型肝炎病毒结构蛋白E1在昆虫细胞中的表达及定位

本文在大肠杆菌中表达了与GST融合无跨膜区的丙型肝炎病毒(Hepatitis C Virus,HCV)E1蛋白,并通过免疫兔制备了兔抗E1的抗血清。然后利用Bac-to-Bac杆状病毒表达系统构建了含有HCV结构蛋白E1基因的重组杆状病毒vAcHCVE1。通过Western blot分析,E1蛋白在Sf9细胞中表达分子量大小为30kDa大于预测的20kDa,表明存在翻译后修饰如糖基化等。通过Confocal显微镜观察当感染48h后E1蛋白定位在细胞质和细胞膜上。     

Ⅲ型中国株HCVE2/NS1基因与已知分离株的同源性比较

利用逆转录套式ＰＣＲ扩增Ⅲ型中国株ＨＣＶＥ２／ＮＳ１基因片段,将其克隆到ｐｃＤＮＡ３载体上．采用双脱氧链终止法测定插入片段的核苷酸序列．并与已知分离株的相应区域进行同源性比较．首次克隆出Ⅲ型中国株ＨＣＶＥ２／ＮＳ１基因（ＨＣ－Ｗ１４）,其核苷酸序列与Ⅲ型日本株ＨＣＶ（ＨＣ－Ｊ６）该区域同源性为８８．３７％,其推定的氨基酸同源性为８９．２９％．而与已知的非Ⅲ型株ＨＣＶ该区域相比,核苷酸及氨基酸的同源性均相对较低．Ⅲ型中国株ＨＣＶ与Ⅱ型中国株ＨＣＶ在Ｅ２／ＮＳ１区域有较大的变异,揭示研制我国的ＨＣＶ疫苗应该考虑这种基因型之间的变异性．     

Two French genotypes of hepatitis C virus: homology of the predominant genotype with the prototype American strain.

A hepatitis C virus (HCV) cDNA covering part of the nonstructural region, NS3, was amplified from the serum of 50 out of 76 French non-A, non-B hepatitis patients by the nested polymerase chain reaction (PCR). Determination of a 407-bp sequence from four such cases revealed the presence of two different virus genotypes, F1 and F2, which exhibited 19-20% sequence divergence. F1 was represented by three of the four isolates and showed a sequence homology of about 97.5% to the prototype American HCV isolate, but of only 79% to a reported Japanese isolate. In contrast, F2 had 91.6% homology to the Japanese isolate, but only 81% homology to the prototype American HCV. PCR products from the 50 samples were hybridized with labeled F1 and F2 fragments under stringent conditions; results indicated the F1-related strain(s) as the major HCV genotype. Furthermore, a total of 1477 bp of sequence has been determined for one of the isolates belonging to the F1 category. These results will have implications for the PCR detection of HCV infection and production of HCV vaccines, especially for European countries.     

12株猪瘟病毒E2基因主要抗原区域的序列差异分析

用RTPCR扩增了12个不同时期分离的HCV毒株E2基因主要抗原区域的cDNA片段并对其进行了序列测定。应用DNAstar序列分析软件对所测的12个HCV毒株与国内外已知的6个毒株Alfort株、Ald株、Brescia株、Gpe株、C株、CW株及早期已测定的HCLV株、HCVSM株和北京顺义株(BJSY2/96)3个毒株的相应片段进行了同源性比较分析。E2基因主要区域长度均为224 bp,包括从HCV 2485到2708位的E2基因B、C区域。所测的疫苗株HCLV与国外测得的疫苗株C株核苷酸及氨基酸同源性分别为991%和100%,表明目前应用的疫苗株是稳定的;用目前我国流行的部分野毒株对HCLV株免疫猪的攻击试验表明,HCLV对野毒株均具有很好的免疫力,这与序列分析结果相吻合。根据系统树分析,可将HCV分为两大群,5株90年代的野毒株及1株80年代的野毒株(其中北京3株、河南2株、广东1株)均与国内外C株、标准株属同一群(即第一群),其核苷酸及氨基酸的同源性分别为857%～100%和838%～100%;与Alfort株同属第二群的有6个野毒株(广西北海、辽宁、河北黄骅、吉林、深圳光明、四川成都),其中80年代与90年代的野毒株各有三株,核苷酸及氨基酸的同源性分别为843%～100%和851%～100%;21株HCV的核苷酸及氨基酸的同源性分别为781%～100%和784%～100%。两群之间的特征性差异表现在713和729位氨基酸位点的不同,经分析发现猪瘟野毒株具有复杂性与多样性。     

Molecular cloning of HCV and clinical application

Abstract: Fifty-five clones encoding epitopes of HCV were isolated from Japanese patients. Their amino acid homology (AAH) to the sequence of prototype (HCV-1) ranged from 47% to 94%. These sequences cover 60% of the HCV genome lacking M/E and NS2 regions suggesting a very low or lacking immunogenecity for these regions. Two test kits for detection of anti-HCV antibody were developed using a combination of a synthetic peptide (AR142) containing the epitope of N14 (QRKTKRSTNRR) having a homology to the core of HCV of | fr | sol 8/11AA and a non-fusion recombinant protein Y19 starting from amino acid number (AAN) 1380 to 1507 in the NS3 region showing a AAH to the HCV-1 of 90%, and a combination of a mixture of three synthetic peptides of S29 AAN of 1–30, 38–65 and 47–74 of the core and a non-fused recombinant protein S4 AAN of 1287–1506 having a 93% AAH of the NS3 region. They showed almost the same order of sensitivity and specificity of the second-generation kits when tested with serum from blood donors and patients with non-A, non-B hepatitis. It should also be stressed that in all of the complete responders of a recombinant α-interferon therapy, the antibody levels against AR142 gradually decreased during and after the treatment. In 1992, studies performed for 125 patients with hepatocellular carcinoma in our clinic shows that of these 16 patients might developed from either chronic non-B, non-C liver diseases or chronic liver diseases caused by mutant(s) of HCV as their serum were negative for HBsAg and second-generation of anti-HCV.     

Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus

The amino terminal region of the non structural gene 3 (NS3) of hepatitis C virus (HCV) is a chymotripsinlike serine-protease responsible for cleavage of the non structural proteins of Hepatitis C virus (HCV). In order to investigate the genetic variation of this region, we developed a nested PCR to obtain NS3 protease sequences from 54 patients chronically infected with HCV genotypes 1a, 1b and 3, respectively. Comparison of nucleotide and amino acids sequences of NS3 protease domain with consensus sequence obtained within the same genotype, showed 3.73% nucleotide divergence and 1.64% amino acid divergence in isolates of genotype 3a, whereas isolates 1a exhibited 4.45% nucleotide and 4% amino acid change, respectively. Finally, NS3 sequence from 1b isolates revealed 6.47% nucleotide and 3.5 % aa changes. Comparison of consensus amino acid sequences derived from isolates 1a, 1b and 3, with the HCV prototypes showed a low amino acid sequence diversity. However, the consensus sequence of HCV genotype 3 isolates showed an amino acid changed from the prototype, that was located within a region important for enzyme structure and activity. These results indicated that the NS3 protease gene is highly conserved within the same HCV genotype. The domains involved in enzyme function were highly conserved in 1a and 1b strains, whereas consensus sequence of isolates 3a showed that the majority of these strains were not perfectly conserved in one of such regions. These findings altogether suggested that the NS3 protease enzyme of HCV may constitute an important target for antiviral therapy, but the NS3 protease variability of isolates 3 within a region that is a potential target for antiviral therapy could pose a problem for structure based drug development.     

Phosphatidylserine-Specific Phospholipase A1 is the Critical Bridge for Hepatitis C Virus Assembly

The phosphatidylserine-specific phospholipase A1(PLA1 A) is an essential host factor in hepatitis C virus(HCV)assembly. In this study, we mapped the E2, NS2 and NS5 A involved in PLA1 A interaction to their lumenal domains and membranous parts, through which they form oligomeric protein complexes to participate in HCV assembly. Multiple regions of PLA1 A were involved in their interaction and complex formation. Furthermore, the results represented structures with PLA1 A and E2 in closer proximity than NS2 and NS5 A, and strongly suggest PLA1 A-E2's physical interaction in cells. Meanwhile, we mapped the NS5 A sequence which participated in PLA1 A interaction with the C-terminus of domain 1. Interestingly, these amino acids in the sequence are also essential for viral RNA replication. Further experiments revealed that these four proteins interact with each other. Moreover, PLA1 A expression levels were elevated in livers from HCV-infected patients. In conclusion, we exposed the structural determinants of PLA1 A, E2, NS2 and NS5 A proteins which were important for HCV assembly and provided a detailed characterization of PLA1 A in HCV assembly.     

Signal Peptidase Complex Subunit 1 Participates in the Assembly of Hepatitis C Virus through an Interaction with E2 and NS2

Hepatitis C virus (HCV) nonstructural protein 2 (NS2) is a hydrophobic, transmembrane protein that is required not only for NS2-NS3 cleavage, but also for infectious virus production. To identify cellular factors that interact with NS2 and are important for HCV propagation, we screened a human liver cDNA library by split-ubiquitin membrane yeast two-hybrid assay using full-length NS2 as a bait, and identified signal peptidase complex subunit 1 (SPCS1), which is a component of the microsomal signal peptidase complex. Silencing of endogenous SPCS1 resulted in markedly reduced production of infectious HCV, whereas neither processing of structural proteins, cell entry, RNA replication, nor release of virus from the cells was impaired. Propagation of Japanese encephalitis virus was not affected by knockdown of SPCS1, suggesting that SPCS1 does not widely modulate the viral lifecycles of the Flaviviridae family. SPCS1 was found to interact with both NS2 and E2. A complex of NS2, E2, and SPCS1 was formed in cells as demonstrated by co-immunoprecipitation assays. Knockdown of SPCS1 impaired interaction of NS2 with E2. Our findings suggest that SPCS1 plays a key role in the formation of the membrane-associated NS2-E2 complex via its interaction with NS2 and E2, which leads to a coordinating interaction between the structural and non-structural proteins and facilitates the early step of assembly of infectious particles.